QUELIMMUNE pediatric surveillance registry
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This registry tracks children treated with QUELIMMUNE therapy to see how well it works over time. It helps doctors learn more about the treatment's safety and effects in kids.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have started or will start QUELIMMUNE therapy for your condition
- You weigh at least 22 pounds (10 kilograms)
- You are 22 years old or younger
- You do not have a known allergy to any part of QUELIMMUNE
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial measures how anti-infective medicines move through a child’s body while they are in the hospital or during follow-up. The goal is to better understand dosing and drug exposure in critically ill children.
This study tests a combination of two medicines, rituximab and low-dose mycophenolate, to treat a type of kidney inflammation called proliferative lupus nephritis in children. It aims to see if the combination works well and is safe for kids with active lupus affecting the kidneys.
This trial tests if dupilumab can help children with nephrotic syndrome who still have relapses despite standard treatments. It aims to find a better way to control the disease and reduce steroid side effects.
This study checks children in pediatric intensive care for possible “immune system problems” after a severe infection. The goal is to find primary immunodeficiencies early, which may change follow-up and treatment for the child’s immune health.
This study tests a new experimental treatment called QUAIL-100 in children and young adults who have had a stem cell transplant for a serious blood cancer. The treatment is designed to help the immune system fight remaining cancer cells.
This trial studies whether rituximab alone can help children with new-onset idiopathic nephrotic syndrome. It compares the treatment approach in order to see if it improves kidney recovery and reduces disease activity.
Hear when a new Acute Kidney Injury trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.